Holen Sie sich die Stockscreener-App
14.22
0.14%
-0.05
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Earns $50M Milestone Payment as Novartis Starts Phase 2 Trial - Minichart
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 - Investing News Network
A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial - Stock Titan
Monte Rosa Announces $50M Milestone as Novartis Starts Phase 2 for MRT-6160 in Sjögren’s - TradingView
Monte Rosa Therapeutics Announces Milestone Achievement - GlobeNewswire
How Investors Are Reacting To Monte Rosa Therapeutics (GLUE) Advancing MRT-2359 Into Phase 2 Prostate Cancer Trial - webull.com
Trading Systems Reacting to (GLUE) Volatility - Stock Traders Daily
Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet - Seeking Alpha
Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new hires get stock awards from Monte Rosa - Stock Titan
GLUE stock gains on investor conference plans and Monte Rosa outlook - AD HOC NEWS
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Is Monte Rosa Therapeutics (GLUE) Redefining Its Prostate Cancer Strategy With MRT-2359’s Phase 2 Combo Bet? - simplywall.st
615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC - MarketBeat
Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Discipline and Rules-Based Execution in GLUE Response - Stock Traders Daily
ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Guggenheim Reaffirms "Buy" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - MarketBeat
Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer - marketscreener.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Monte (GLUE) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Current Update; Session Move - vinanet.vn
Monte (GLUE) Shares: Finishes 6.28% Lower at $14.78 in Latest Trading; Key Range: the $14.04 to $15.52 Range Remains in Focus for the Current SessionSentiment Divergence - vinanet.vn
Monte (GLUE) Market Snapshot: Moves 1.30% Lower to $15.18 for the Current Session - vinanet.vn
Alphabet Inc. Buys Shares of 372,474 Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE) - simplywall.st
Monte Rosa Therapeutics (GLUE) holders report sub‑5% stakes in amended 13G - Stock Titan
Monte Rosa Therapeutics (GLUE): Vestal Point discloses 4.6M-share, 5.4% ownership - Stock Titan
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - The Globe and Mail
Industry Analysts Just Upgraded Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Revenue Forecasts By 21% - webull.com
Why Monte Rosa Therapeutics (GLUE) Is Back In Focus After Its Latest Update - Sahm
Analysts Are Upgrading Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) After Its Latest Results - webull.com
What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results - marketbeat.com
MONTE ROSA THERAPEUTICS, INC. : WELLS FARGO CUTS TARGET PRICE TO $27 FROM $29 - webull.com
Monte Rosa Therapeutics, Inc. (GLUE) stock price, news, quote and history - Yahoo Finance Singapore
The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE - marketbeat.com
Monte Rosa Therapeutics (GLUE) Climbs 1.08% as Shares Hold Above Key Support at $15.09Time Weighted Price - vinanet.vn
JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - MarketBeat
Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00 - marketbeat.com
Monte Rosa Therapeutics Is Maintained at Overweight by Wells Fargo - Moomoo
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
Monte Rosa Therapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
(GLUE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Monte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingView
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D - TradingView
Monte Rosa posts $43.4 million Q2 loss as pipeline trials advance - Quiver Quantitative
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, Vs. FactSet Est of $12.9M - Moomoo
Monte Rosa Therapeutics reports Q2 2026 net loss $43.4M, cash position $626.0M supporting operations into 2029 - TradingView
Monte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingView
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):